Is Califf’s Nomination for FDA Chief In Trouble?
Robert Califf’s return to the top job at the FDA is in peril, reports Politico. But another news source predicts the Senate will eventually vote in favor of making him the FDA commissioner for a second time.
The Biden’s administration tortuous journey to having a permanent FDA commissioner continues to have twist and turns.
The administration waited nearly 10 months before settling on Robert Califf, M.D., as a nominee in November. Politico reported today that “Califf’s supporters fear his candidacy is on the brink” and that the White is House is asking Anthony Fauci and other advisers to help “rescue the nomination.”
“If the vote was held today, he would not have the vote,” Politico quoted an unnamed source as saying.
‘White House isn’t supporting him’: Biden’s FDA pick left in limbo,” was the headline on the story, which is, however, largely based on unnamed sources.
A Bloomberg Law story posted on Monday cast Califf’s chances in a more optimistic light. Echoing statements made when Califf was nominated in November, the Bloomberg Law story says that Califf’s “previous stint as FDA chief will help him secure the role once again despite growing lawmaker opposition over this drug company ties.”
Politico reported that five Democrats — Sens. Bernie Sanders (I-Vt.), Joe Manchin (D-W.Va.), Ed Markey (D-Mass.), Maggie Hassan (D-N.H.) and Richard Blumenthal (D-Conn.) — have signaled opposition to Califf’s nomination.
The Senate Health, Education, Labor, and Pensions Committee voted 13-8 in favor of Califf’s nomination two weeks ago. Sanders and Hassan voted against forwarding his name.
Califf has been criticized by Democrats for his ties to the pharmaceutical industry, which have included consulting fees and other financial arrangements. His supporters tend to speak of his experience and expertise in clinical trials.
Califf, a cardiologist, was FDA commissioner from Feb. 2016 through Jan. 2017.
Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
